Table 3.

Clinical data of a cohort of pediatric multiple sclerosis (MS) patients treated with immunomodulatory agents, after a long-term follow up [Ghezzi et al. 2009a].

	Avonex n = 77	Rebif/Betaferon n = 39	Copaxone n = 14
Mean age of MS onset	11.4 ± 3.1	12.6 ± 2.6	13.1 ± 1.5
Treatment duration	53. ± 27.0	59.9 ± 39.5	74.6 ± 35.5
Annualized pretreatment relapse rate	2.5 ± 1.9	3.2 ± 2.5	2.9 ± 1.8
Relapse rate during the treatment	0.4 ± 0.6	0.9 ± 1.1	0.2 ± 0.3
EDSS pretreatment	1.3 ± 1.0	1.7 ± 0.8	1.1 ± 0.4
Final EDSS	1.5 ± 1.2	2.0 ± 1.4	1.0 ± 0.9

EDSS, Expanded Disability Status Scale.